Screening is the first step to treatment
HIV, STIs, VIRAL HEPATITIS AND LTBI ROUTINE SCREENING TOOLKIT

Clinical Workflow Algorithm: Hepatitis B (HBV) Screening

This document translates screening guidance and clinical considerations from the USPSTF and CDC into a decision tree format to guide implementation.

WHO TO SCREEN

— Adolescents and adults at increased risk for HBV infection
— Pregnant persons

If screening criteria are met

TEST TO USE
Hepatitis B surface antigen (HbsAg) tests

POSITIVE
Conduct confirmatory test, Hepatitis B surface antibody (anti-HBs) and Hepatitis B core antibody (anti-HBc).

NEGATIVE
If susceptible and eligible, recommend vaccination.

CHRONIC INFECTION
Antiviral medications are available. Link to care with regular monitoring.
See AASLD practice guidelines:
https://www.aasld.org/publications/practiceguidelines

ACUTE INFECTION
Provide supportive treatment depending on symptoms.

PREGNANT PERSONS
HBV DNA viral load testing and referral to specialty care for counseling and medical management
See:
https://www.cdc.gov/hepatitis/hbv/pdfs/PrenatalHBsAgTesting_508.pdf

INFANTS
HBV vaccination within 12 hours of birth, followed by HBIG prophylaxis

IMPLEMENTATION CONSIDERATIONS

1 Test frequency
Periodically screen persons with continued risk for HBV infection.
Pregnant persons should be tested at first prenatal visit, for each pregnancy, and those with unknown HBsAg status or risk factors for HBV infection should be screened at admission for delivery.

2 Acute infection
• HBsAg positive
• Anti-HBc positive
• IgM anti-HBc positive
• Anti-HBs negative.

3 Chronic infection
• HBsAg positive
• Anti-HBc positive
• IgM anti-HBc negative
• Anti-HBs negative

4 ACIP HBV vaccine recommendations
The HBV vaccine is recommended for all infants, all children or adolescents younger than 19 who have not been vaccinated, all adults age 19 through 59 years, and adults age 60 years or older with risk factors for infection.
Adults who are 60+ without known risk factors may also receive the vaccine.
See:
https://www.cdc.gov/mmwr/volumes/67/rr/rr6701a1.htm

© 2023 American Medical Association. All rights reserved. 22-757143-HIV-9/22